Gene Therapy for X-linked Severe Combined Immunodeficiency (NCT01410019) | Clinical Trial Compass
CompletedPhase 1/2
Gene Therapy for X-linked Severe Combined Immunodeficiency
France5 participantsStarted 2010-12
Plain-language summary
X-linked severe combined immunodeficiency (SCID-X1) is an inherited disorder that results in failure of development of the immune system in boys. This trial aims to treat SCID-X1 patients using gene therapy to replace the defective gene.
Who can participate
Age range12 Months
SexMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria :
* Boys diagnosed during the first year of life
* Diagnosis of classical SCID-X1 based on immunophenotype (absent, or reduced numbers of non-functional T lymphocytes) and confirmed by DNA sequencing
* No HLA identical family donor and no HLA identical unrelated donor (10/10 antigens) found in the 6 weeks following the beginning of the search. This period could be shortened if the probability to find a donor is low or if the clinical situation (gravity) required
* Presence of a severe infection: pneumonitis and / or chronic diarrhea, or infection with herpes viruses or parainfluenza type 3 or adenovirus, or disseminated BCG infection, or presence of severe diarrhea and a severe compromise of the general state with denutrition
* Or failure of a HLA HAPLO-identical bone marrow transplant within 10 years after transplantation
* In all cases:
* No family background of cancer in childhood.
* No cytogenetic abnormalities (medullary karyotype) and no detection of main rearrangements associated with acute leukemia of children
* Parental/guardian voluntary consent
Exclusion criteria :
* Atypical health with autologous T\> 500/ml3
* Infection by HIV 1 or 2
* Allogeneic HSC completed (excluding situations of failure)
* Existence of an HLA identical family donor or HLA identical unrelated donor
* No severe infections in a child with a preserved general state
* Family background of cancer in childhood
* Detection of cytogenetic abnormality and / or rearrangeme…
What they're measuring
1
Assessment of immunological reconstitution at short term